

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 August 2022 (18.08.2022)



(10) International Publication Number
WO 2022/171813 A3

(51) International Patent Classification:

CI2N 15/11 (2006.01) A61K 31/7088 (2006.01)
CI2N 15/113 (2010.01) A61P 35/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/053407

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

11 February 2022 (11.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(88) Date of publication of the international search report:

22 September 2022 (22.09.2022)

(30) Priority Data:

2102118.3 15 February 2021 (15.02.2021) GB

(71) Applicant: CAMBRIDGE ENTERPRISE LIMITED

[GB/GB]; The Old Schools, Trinity Lane, Cambridge Cam-
bridgeshire CB2 1TN (GB).

(72) Inventors: INGEMARSDOTTER, Carin; c/o Spliceor

Ltd, Salisbury House, Station Road, Cambridge Cam-
bridgeshire CB1 2LA (GB). LEVER, Andrew; c/o Splice-
or Ltd, Salisbury House, Station Road, Cambridge Cam-
bridgeshire CB1 2LA (GB).

(74) Agent: MEWBURN ELLIS LLP; Aurora Building, Coun-

terslip Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: RNA TRANS-SPLICING MOLECULE

(57) Abstract: This invention relates to an RNA trans- splicing molecule (RTM) that targets human endogenous retrovirus (HERV) pre-mRNA. The RTM comprises (i) a binding region specific for a HERV pre-mRNA, (ii) a trans- splicing splice domain and (iii) a coding sequence for a suicide protein. The binding region of the RTM binds to HERV pre-mRNA in a cell, such that the coding sequence is trans- spliced through the trans- splicing domain with the HERV pre-mRNA, resulting in a chimeric mRNA causing the suicide protein to be expressed in the cell. RTMs of the invention may be useful in selectively killing cells that express HERV genes, for example cancer cells. RTMs, encoding nucleic acids, methods of treatment and associated methods and uses are provided.



WO 2022/171813 A3